Core Viewpoint - The company reported stable revenue performance in the first half of 2025, supported by growth in tissue sales and an increase in market share, despite intense price competition in the sanitary products sector [1] Group 1: Financial Performance - The company's overall revenue slightly decreased by 0.2% year-on-year to approximately RMB 11.808 billion [1] - Overall gross profit fell by about 3.2% to approximately RMB 3.812 billion, with a gross margin declining to around 32.3% [1] - Operating profit decreased by 7.3% to approximately RMB 1.757 billion [1] - Profit attributable to equity holders decreased by approximately 2.6% to around RMB 1.372 billion, with basic earnings per share at RMB 1.206 [1] - The board declared an interim dividend of RMB 0.70 per share [1] Group 2: Sales and Market Strategy - The steady increase in tissue sales is expected to support overall revenue stability in the second half of 2025, driven by multi-channel sales, product personalization, and stable pricing strategies [1] - The company is seizing opportunities in diversified consumer channels, increasing efforts in e-commerce and new retail markets, with e-commerce and new retail sales accounting for approximately 34.4% of total sales, showing a year-on-year growth of about 7.9% [1] - The company continues to promote sales through traditional channels and develop new growth points, with a steady advancement of its multi-channel sales strategy [1] Group 3: Product Development and Brand Enhancement - The company is actively developing new technologies to enhance product high-end features and diversify its product portfolio, responding to the growing demand for personalized and value-added sanitary products [2] - Key high-end products include the "Tianshan Velvet Cotton" sanitary napkin series and the "Q • MO" series of high-end diapers, which have maintained strong sales momentum [2] - New product launches, such as the "Cranberry A+" organic cotton sanitary napkin and the "Towards the Wild" high-end tissue series, are expected to increase the proportion of high-end products in sales and enhance brand image and product reputation [2]

恒安国际(01044)发布公告，该公司将于2025年10月10日派发中期股息每股0.7元人民币。 ...

智通财经APP讯，恒安国际(01044)发布公告，该公司将于2025年10月10日派发中期股息每股0.7元人民 币。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1044） http://www.hengan.com http://www.irasia.com/listco/hk/hengan 網址： 「追求健康，你我一起成長」 | 財務摘要 | | | | | --- | --- | --- | --- | | 二零二五年六月三十日止六個月之中期業績 | | | | | | 未經審核 | | | | 二零二五年 | | 二零二四年 | 變幅 | | 人民幣千元 | | 人民幣千元 | % | | 收入 | 11,808,232 | 11,835,893 | (0.2)% | | 毛利率 | 32.3% | 33.3% | | | 經營利潤 | 1,757,339 | 1,895,891 | (7.3)% | | 公司權益持有人應佔利潤 | 1,372,894 | 1,408,992 | (2.6)% | | 每股收 ...

EF001 免責聲明 | EF001 | | --- | | 其他信息 | | | --- | --- | | 其他信息 | 不適用 | | 發行人董事 | | | | 於本公告刊發日期, 恒安國際集團有限公司董事會成員為: | | 執行董事 | | | 施文博先生 | | | 許清流先生 | | | 許大座先生 | | | 施煌劍先生 | | | 許清池先生 | | | 李偉樑先生 | | | 許文默先生 | | | 獨立非執行董事 | | | 黃英琦女士 | | | 何貴清先生 | | | 保羅希爾先生 | | | 陳闖先生 | | 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 恒安國際集團有限公司 | | 股份代號 | 01044 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 ...

格隆汇8月6日丨恒安国际(01044.HK)宣布，公司将于2025年8月21日(星期四)举行董事会会议，藉以(其 中包括)批准刊发集团截至2025年6月30日止六个月的中期业绩公告，以及考虑派发中期股息(如有)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） 主席 施文博 香港，二零二五年八月六日 於本公告日期，董事會包括執行董事施文博先生、許清流先生、許大座先生、施煌 劍先生、許清池先生、李偉樑先生和許文默先生；及獨立非執行董事保羅希爾先 生、黃英琦女士、何貴清先生和陳闖先生。 恒安國際集團有限公司 http://www.hengan.com http://www.irasia.com/listco/hk/hengan 網址： 董事會召開日期 恒安國際集團有限公司（「本公司」，及其附屬公司統稱「本集團」）之董事會（「董事 會」）謹此宣佈，本公司將於二零二五年八月二十一日（星期四）舉行董事會會議，藉 以（其中包括）批准刊發本集團截至二零二五年六月三十日止六個月的中期業績公 告，以及考慮派發中期股息（如有）。 承董事會命 （股份代號：1044） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 恒安國際集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01044 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.1 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.1 | HKD | | 300,000,000 | 本月底法定/註冊股本 ...

Core Viewpoint - CICC has downgraded Hengan International's 2025 net profit forecast by 26% to 2.29 billion HKD, while introducing a new profit estimate of 2.412 billion HKD for 2026, maintaining a neutral rating and reducing the target price by 15% to 25.5 HKD, indicating a potential upside of 9.7% from the current stock price [1] Group 1 - The firm expects a slight decline in revenue for H1 2025, with comparable net profit (excluding foreign exchange gains and losses) anticipated to decrease by single digits, aligning with market expectations [2] - Hengan's tissue business is projected to show single-digit growth in H1 2025, driven by sales volume, strong performance in high-end products, and channel expansion, while the sanitary napkin business is expected to face pressure with a low double-digit decline [3] - The company is expected to maintain a manageable promotional effort in the sanitary napkin segment despite increased competition from domestic brands [3] Group 2 - The firm predicts that pulp prices will remain low in H1 2025, leading to manageable cost pressures, with expectations of improved gross margins for the tissue and sanitary napkin businesses due to favorable cost conditions and production scale effects [4] - The overall expense ratio is expected to rise slightly due to increased competitive pressures, although the company’s promotional spending is anticipated to remain controlled [4] - The company aims to continue driving revenue growth through product premiumization and channel diversification, with expectations for improved performance in tissue, wet wipes, and diaper segments in the latter half of the year [4]

Core Viewpoint - Hengan International Group Co., Ltd. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [2]. - The recent upgrade for Hengan International Group Co. suggests an improvement in its earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, which influences their buying and selling decisions, thereby affecting stock prices [5]. Performance of Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks averaging a +25% annual return since 1988 [8]. - Hengan International Group Co. is positioned in the top 20% of Zacks-covered stocks, indicating its strong earnings estimate revision feature and potential for market-beating returns [10][11]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, Hengan International Group Co. is expected to earn $1.43 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 3.6% over the past three months [9].